Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 85,777 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Completed Phase 2 Interventional Results available

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

NCT01903031
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Nuvaring, EFV, ATV/r, TDF, NRTIs
Device · Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 28, 2026, 5:28 PM EDT
Suspended Phase 1 Interventional

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

NCT05685602
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Gemcitabine Hydrochloride, Nab-paclitaxel
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2Phase 3 Interventional

Recovery Housing For Drug Dependent Pregnant Women

NCT00497302
View directory record Official record
Conditions
Drug Addiction
Interventions
RBT, usual care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT02153502
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

NCT03421353
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhanced Gait and Balance Training

NCT01896466
View directory record Official record
Conditions
Aging, Accidental Falls
Interventions
Cranial Nerve Non-Invasive Neuromodulation, Sham Cranial Nerve Non-Invasive Neuromodulation
Device · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 95 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 28, 2026, 5:28 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

NIH Intramural Research Program s Pregnancy Registry Protocol for Subjects and Their Partners

NCT04977466
View directory record Official record
Conditions
Pregnancy Outcome
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
1 Day to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2045
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Radiosurgery or Open Surgery for Epilepsy Trial

NCT00860145
View directory record Official record
Conditions
Epilepsy
Interventions
radiosurgery, temporal lobectomy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 28, 2026, 5:28 PM EDT
Active, not recruiting Phase 1 Interventional

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

NCT02091245
View directory record Official record
Conditions
Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis
Interventions
KPT-330
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
12 Months to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Task Control Circuit Targets for Obsessive Compulsive Behaviors in Children

NCT03584945
View directory record Official record
Conditions
Obsessive-compulsive Disorders and Symptoms in Children
Interventions
Cognitive Behavioral Therapy, Community Referral as appropriate
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 14 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Results available

Feasibility Pilot of Bright Light in the Intensive Care Unit

NCT03568045
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorder, Unspecified
Interventions
standard light, 10,000 lux bright light, 4 hours, 10,000 lux bright light, 8 hours
Device
Lead sponsor
Yale University
Other
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Low Intensity Ultrasound Neuromodulation of Repetitive Negative Thinking In Depression

NCT05697172
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low-intensity focused ultrasound
Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 28, 2026, 5:28 PM EDT
Completed No phase listed Observational

Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course

NCT02301572
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
0 Years to 89 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

NCT00656539
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 28, 2026, 5:28 PM EDT
Completed No phase listed Observational

Effects Of Invasive And Noninvasive Mechanical Ventilation On Sleep In The Intensive Care Unit (ICU)

NCT00638339
View directory record Official record
Conditions
Respiratory Insufficiency, Respiration, Artificial, Sleep Deprivation
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

NCT01882439
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 28, 2026, 5:28 PM EDT
Terminated Phase 3 Interventional

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

NCT02664077
View directory record Official record
Conditions
Stage III (IIIB or IIIC) Colon Cancer
Interventions
Regorafenib, Placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Orange, California • Santa Rosa, California • Vallejo, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Video Games for Obesity and Diabetes Prevention-Diab & Nano

NCT01846377
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
G4H-Diab-Nano
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Interaction Study of LY3200882 in Healthy Participants

NCT03792139
View directory record Official record
Conditions
Healthy
Interventions
LY3200882, Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

NCT05048875
View directory record Official record
Conditions
Dengue
Interventions
Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

NCT01756157
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE with rHuPH20
Biological
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of CC-292

NCT02433457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-292, Oral Omeprazole (OMP)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

NCT01631201
View directory record Official record
Conditions
Chlamydia Trachomatis Infection
Interventions
Rifalazil 25 milligram, Azithromycin 1 gram
Drug
Lead sponsor
ActivBiotics Pharma, LLC
Industry
Eligibility
19 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 28, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 28, 2026, 5:28 PM EDT